Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.

Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuoglio D, Iuliano A, Del Bufalo D, Di Bernardo D, Melisi D, Draetta GF, Ciliberto G, Carugo A, Cardone L.

Cancer Res. 2019 Nov 1;79(21):5612-5625. doi: 10.1158/0008-5472.CAN-19-0187. Epub 2019 Sep 5.

PMID:
31492820
2.

Emerging Role of Histone Acetyltransferase in Stem Cells and Cancer.

Trisciuoglio D, Di Martile M, Del Bufalo D.

Stem Cells Int. 2018 Dec 16;2018:8908751. doi: 10.1155/2018/8908751. eCollection 2018. Review.

3.

Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.

D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominici M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuoglio D, Del Bufalo D.

J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.

4.

Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.

Iachettini S, Trisciuoglio D, Rotili D, Lucidi A, Salvati E, Zizza P, Di Leo L, Del Bufalo D, Ciriolo MR, Leonetti C, Steegborn C, Mai A, Rizzo A, Biroccio A.

Cell Death Dis. 2018 Sep 24;9(10):996. doi: 10.1038/s41419-018-1065-0.

5.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.

J Exp Clin Cancer Res. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5.

6.

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.

Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R.

Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6.

7.

Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.

Di Martile M, Desideri M, Tupone MG, Buglioni S, Antoniani B, Mastroiorio C, Falcioni R, Ferraresi V, Baldini N, Biagini R, Milella M, Trisciuoglio D, Del Bufalo D.

Oncogenesis. 2018 Feb 23;7(2):20. doi: 10.1038/s41389-018-0026-x.

8.

BCL-XL overexpression promotes tumor progression-associated properties.

Trisciuoglio D, Tupone MG, Desideri M, Di Martile M, Gabellini C, Buglioni S, Pallocca M, Alessandrini G, D'Aguanno S, Del Bufalo D.

Cell Death Dis. 2017 Dec 13;8(12):3216. doi: 10.1038/s41419-017-0055-y.

9.

A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.

Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.

FEBS J. 2018 Jan;285(1):127-145. doi: 10.1111/febs.14324. Epub 2017 Dec 2.

10.

Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.

Gabellini C, Gómez-Abenza E, Ibáñez-Molero S, Tupone MG, Pérez-Oliva AB, de Oliveira S, Del Bufalo D, Mulero V.

Int J Cancer. 2018 Feb 1;142(3):584-596. doi: 10.1002/ijc.31075. Epub 2017 Oct 12.

11.

Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization.

Ferrara M, Sessa G, Fiore M, Bernard F, Asteriti IA, Cundari E, Colotti G, Ferla S, Desideri M, Buglioni S, Trisciuoglio D, Del Bufalo D, Brancale A, Degrassi F.

Oncogene. 2018 Jan 11;37(2):231-240. doi: 10.1038/onc.2017.320. Epub 2017 Sep 18.

12.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4671-4672. doi: 10.1038/onc.2017.212. Epub 2017 Jun 19.

PMID:
28628115
13.

Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma.

Fianco G, Mongiardi MP, Levi A, De Luca T, Desideri M, Trisciuoglio D, Del Bufalo D, Cinà I, Di Benedetto A, Mottolese M, Gentile A, Centonze D, Ferrè F, Barilà D.

Elife. 2017 Jun 8;6. pii: e22593. doi: 10.7554/eLife.22593.

14.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4573-4584. doi: 10.1038/onc.2017.75. Epub 2017 Apr 3. Erratum in: Oncogene. 2017 Jun 19;:.

PMID:
28368399
15.

Metabolite profiling of ascidian Styela plicata using LC-MS with multivariate statistical analysis and their antitumor activity.

Palanisamy SK, Trisciuoglio D, Zwergel C, Del Bufalo D, Mai A.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):614-623. doi: 10.1080/14756366.2016.1266344.

16.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

17.

Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.

Gabellini C, Trisciuoglio D, Del Bufalo D.

Carcinogenesis. 2017 Jun 1;38(6):579-587. doi: 10.1093/carcin/bgx016. Review.

PMID:
28203756
18.

The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target.

Di Martile M, Del Bufalo D, Trisciuoglio D.

Oncotarget. 2016 Aug 23;7(34):55789-55810. doi: 10.18632/oncotarget.10048. Review.

19.

Erratum: Kinetochore-microtube attachments in cancer therapy.

Del Bufalo D, Degrassi F.

Oncoscience. 2016 Feb 4;3(1):49. eCollection 2016.

20.

Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.

Di Martile M, Desideri M, De Luca T, Gabellini C, Buglioni S, Eramo A, Sette G, Milella M, Rotili D, Mai A, Carradori S, Secci D, De Maria R, Del Bufalo D, Trisciuoglio D.

Oncotarget. 2016 Mar 8;7(10):11332-48. doi: 10.18632/oncotarget.7238.

21.

Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein.

Trisciuoglio D, Desideri M, Farini V, De Luca T, Di Martile M, Tupone MG, Urbani A, D'Aguanno S, Del Bufalo D.

Cell Death Dis. 2016 Feb 11;7:e2090. doi: 10.1038/cddis.2015.357.

22.

NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and Neoangiogenesis.

Favia A, Pafumi I, Desideri M, Padula F, Montesano C, Passeri D, Nicoletti C, Orlandi A, Del Bufalo D, Sergi M, Ziparo E, Palombi F, Filippini A.

Sci Rep. 2016 Jan 6;6:18925. doi: 10.1038/srep18925.

23.

Kinetochore-microtube attachments in cancer therapy.

Del Bufalo D, Degrassi F.

Oncoscience. 2015 Nov 16;2(11):902-3. eCollection 2015. No abstract available. Erratum in: Oncoscience. 2016;3(1):49.

24.

1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells.

Valente S, Mellini P, Spallotta F, Carafa V, Nebbioso A, Polletta L, Carnevale I, Saladini S, Trisciuoglio D, Gabellini C, Tardugno M, Zwergel C, Cencioni C, Atlante S, Moniot S, Steegborn C, Budriesi R, Tafani M, Del Bufalo D, Altucci L, Gaetano C, Mai A.

J Med Chem. 2016 Feb 25;59(4):1471-91. doi: 10.1021/acs.jmedchem.5b01117. Epub 2016 Jan 5.

PMID:
26689352
25.

miR-211 and MITF modulation by Bcl-2 protein in melanoma cells.

De Luca T, Pelosi A, Trisciuoglio D, D'Aguanno S, Desideri M, Farini V, Di Martile M, Bellei B, Tupone MG, Candiloro A, Regazzo G, Rizzo MG, Del Bufalo D.

Mol Carcinog. 2016 Dec;55(12):2304-2312. doi: 10.1002/mc.22437. Epub 2015 Nov 24.

PMID:
26599548
26.

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Mariano G, Ricciardi MR, Trisciuoglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, Del Bufalo D, Caiafa P, Reale A.

Oncotarget. 2015 Jun 20;6(17):15008-21.

27.

TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo.

Gambara G, Desideri M, Stoppacciaro A, Padula F, De Cesaris P, Starace D, Tubaro A, Del Bufalo D, Filippini A, Ziparo E, Riccioli A.

J Cell Mol Med. 2015 Feb;19(2):327-39. doi: 10.1111/jcmm.12379. Epub 2014 Dec 2.

28.

VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling.

Favia A, Desideri M, Gambara G, D'Alessio A, Ruas M, Esposito B, Del Bufalo D, Parrington J, Ziparo E, Palombi F, Galione A, Filippini A.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4706-15. doi: 10.1073/pnas.1406029111. Epub 2014 Oct 20.

29.

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.

Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuoglio D.

Mol Cancer. 2014 Oct 9;13:230. doi: 10.1186/1476-4598-13-230.

30.

N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics.

Orticello M, Fiore M, Totta P, Desideri M, Barisic M, Passeri D, Lenzi J, Rosa A, Orlandi A, Maiato H, Del Bufalo D, Degrassi F.

Oncogene. 2015 Jun;34(25):3325-35. doi: 10.1038/onc.2014.265. Epub 2014 Aug 18.

PMID:
25132262
31.

CRBP-1 expression in ovarian cancer: a potential therapeutic target.

Doldo E, Costanza G, Ferlosio A, Passeri D, Bernardini S, Scioli MG, Mazzaglia D, Agostinelli S, Del Bufalo D, Czernobilsky B, Orlandi A.

Anticancer Res. 2014 Jul;34(7):3303-12.

PMID:
24982334
32.

1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.

Valente S, Trisciuoglio D, De Luca T, Nebbioso A, Labella D, Lenoci A, Bigogno C, Dondio G, Miceli M, Brosch G, Del Bufalo D, Altucci L, Mai A.

J Med Chem. 2014 Jul 24;57(14):6259-65. doi: 10.1021/jm500303u. Epub 2014 Jul 8.

PMID:
24972008
33.

Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumors.

Pelosi A, Careccia S, Sagrestani G, Nanni S, Manni I, Schinzari V, Martens JH, Farsetti A, Stunnenberg HG, Gentileschi MP, Del Bufalo D, De Maria R, Piaggio G, Rizzo MG.

Mol Cancer Res. 2014 Jun;12(6):878-89. doi: 10.1158/1541-7786.MCR-13-0410. Epub 2014 Mar 17.

34.

BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.

Gabellini C, De Luca T, Trisciuoglio D, Desideri M, Di Martile M, Passeri D, Candiloro A, Biffoni M, Rizzo MG, Orlandi A, Del Bufalo D.

Carcinogenesis. 2013 Nov;34(11):2558-67. doi: 10.1093/carcin/bgt242. Epub 2013 Jul 8.

PMID:
23836782
35.

Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness.

Scarpino S, Duranti E, Giglio S, Di Napoli A, Galafate D, Del Bufalo D, Desideri M, Socciarelli F, Stoppacciaro A, Ruco L.

Thyroid. 2013 Sep;23(9):1127-37. doi: 10.1089/thy.2011.0421. Epub 2013 Aug 27.

PMID:
23617728
36.

tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.

Valente S, Trisciuoglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, Del Bufalo D, Mai A, Cosconati S.

ChemMedChem. 2013 May;8(5):800-11. doi: 10.1002/cmdc.201300005. Epub 2013 Mar 25.

PMID:
23526814
37.

Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth.

Trisciuoglio D, De Luca T, Desideri M, Passeri D, Gabellini C, Scarpino S, Liang C, Orlandi A, Del Bufalo D.

Neoplasia. 2013 Mar;15(3):315-27.

38.

The thiazole derivative CPTH6 impairs autophagy.

Ragazzoni Y, Desideri M, Gabellini C, De Luca T, Carradori S, Secci D, Nescatelli R, Candiloro A, Condello M, Meschini S, Del Bufalo D, Trisciuoglio D.

Cell Death Dis. 2013 Mar 7;4:e524. doi: 10.1038/cddis.2013.53.

39.

LMNA knock-down affects differentiation and progression of human neuroblastoma cells.

Maresca G, Natoli M, Nardella M, Arisi I, Trisciuoglio D, Desideri M, Brandi R, D'Aguanno S, Nicotra MR, D'Onofrio M, Urbani A, Natali PG, Del Bufalo D, Felsani A, D'Agnano I.

PLoS One. 2012;7(9):e45513. doi: 10.1371/journal.pone.0045513. Epub 2012 Sep 26.

40.

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D'Atri S.

Biochem Pharmacol. 2012 Sep 1;84(5):598-611. doi: 10.1016/j.bcp.2012.06.004. Epub 2012 Jun 13.

PMID:
22704958
41.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.

J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8.

PMID:
22399013
42.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.

Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M.

J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4.

PMID:
22215152
43.

CPTH6, a thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells.

Trisciuoglio D, Ragazzoni Y, Pelosi A, Desideri M, Carradori S, Gabellini C, Maresca G, Nescatelli R, Secci D, Bolasco A, Bizzarri B, Cavaliere C, D'Agnano I, Filetici P, Ricci-Vitiani L, Rizzo MG, Del Bufalo D.

Clin Cancer Res. 2012 Jan 15;18(2):475-86. doi: 10.1158/1078-0432.CCR-11-0579. Epub 2011 Nov 8.

44.

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.

Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone GM, Quatrale AE, Chiarappa P, Mangia A, Sebastian S, Del Bufalo D, Del Tacca M, Paradiso A.

Br J Cancer. 2011 Mar 1;104(5):769-80. doi: 10.1038/bjc.2011.21. Epub 2011 Feb 8.

45.

Lost in translation: bridging the gap between cancer research and effective therapies.

Del Bufalo D, Bagnato A, Fusco A, Milella M.

Cell Death Differ. 2011 Jun;18(6):1082-4. doi: 10.1038/cdd.2010.186. Epub 2011 Jan 21. No abstract available.

46.

Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.

Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca T, Ziparo E, Del Bufalo D.

Cell Death Differ. 2011 Jun;18(6):1024-35. doi: 10.1038/cdd.2010.175. Epub 2011 Jan 14.

47.

Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.

Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D.

PLoS One. 2010 Jul 27;5(7):e11772. doi: 10.1371/journal.pone.0011772.

48.

Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.

Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De Cesaris P, Ziparo E, Del Bufalo D, Sitkovsky MV, Filippini A, Riccioli A.

Neoplasia. 2010 Jul;12(7):539-49.

49.

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G.

Nat Struct Mol Biol. 2009 Oct;16(10):1086-93. doi: 10.1038/nsmb.1669. Epub 2009 Sep 27.

PMID:
19783986
50.

Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.

Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D.

Eur J Cancer. 2009 Sep;45(14):2618-27. doi: 10.1016/j.ejca.2009.07.007. Epub 2009 Aug 13.

PMID:
19683430

Supplemental Content

Loading ...
Support Center